T-Cell Therapy Market by Modality, Therapy Type, Indication - Global Forecast 2025-2030- Product Image

Sale

T-Cell Therapy Market by Modality, Therapy Type, Indication - Global Forecast 2025-2030

Report
182 Pages
October 2024
Region: Global
360iResearch™
ID: 5470745

UP TO €692EUR$697USD£574GBP OFF until Dec 31^st 2024

The T-Cell Therapy Market grew from USD 8.13 billion in 2023 to USD 9.85 billion in 2024. It is expected to continue growing at a CAGR of 21.23%, reaching USD 31.30 billion by 2030.

T-Cell therapy, particularly CAR-T (Chimeric Antigen Receptor T-Cell) therapy, represents an innovative approach in cancer treatment, wherein patients' T-cells are genetically engineered to better recognize and combat cancer cells. The necessity for these therapies arises from their potential to treat cancers unresponsive to conventional therapies, portraying significant efficacy against certain types of blood cancers. The applicability of T-Cell therapy is broad, encompassing numerous cancer types, with expanding investigations in solid tumors. This therapy is contributing significantly to the oncology sector, presenting an advanced treatment avenue with potential application in auto-immune diseases and infectious diseases. Market insights indicate that the industry's growth is influenced by factors such as increased cancer incidence, advancements in genetic engineering, and supportive regulatory environments. Furthermore, strategic alliances and collaborations among pharmaceutical companies bolster R&D, enhancing the market's potential. Notably, opportunities exist in expanding indications, personalized treatments, and geographic market expansion. However, challenges persist, including high treatment costs, complex manufacturing processes, and potential severe side effects, which may deter widespread adoption. The scalability of production and the need for specialized facilities further complicate traditional market expansion. The competitive landscape is dynamic, with ongoing research aiming to improve safety profiles, augment efficacy, and reduce production costs. Innovation areas include developing next-generation T-Cell therapies, focusing on off-the-shelf solutions, and enhancing the persistence and potency of engineered T-Cells. Continuous investment in these areas could overcome existing barriers, propelling market growth. A multidisciplinary approach incorporating genomics, bioinformatics, and individualized medicine is crucial to advancing therapeutic options. Thus, businesses can leverage the ongoing interest in precision oncology and the evolving technological landscape to drive growth, ensuring they remain competitive in this burgeoning market by prioritizing collaborations and agile adaptability.

Understanding Market Dynamics in the T-Cell Therapy Market

The T-Cell Therapy Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Increasing approvals along with expanding manufacturing capabilities
- Alarming rate of increase in prevalence of cancers
- Availability of adequate reimbursements with government awareness
Market Restraints
- Limitations of efficacy of CAR T-cell immunotherapy and inadequate homing of CAR T-cells to tumor deposits
Market Opportunities
- Exponential R&D funding for immuno-oncology sector
- Expanding adoption of gene and cell therapy
Market Challenges
- Safety issues and possible side-effects

Exploring Porter’s Five Forces for the T-Cell Therapy Market

Porter’s Five Forces framework further strengthens the insights of the T-Cell Therapy Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the T-Cell Therapy Market

External macro-environmental factors deeply influence the performance of the T-Cell Therapy Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the T-Cell Therapy Market

The T-Cell Therapy Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the T-Cell Therapy Market

The T-Cell Therapy Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the T-Cell Therapy Market

The T-Cell Therapy Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the T-Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Therapeutics PLC, Amgen Inc., Bluebird Bio, Inc., Bristol Myers Squibb, DiaCarta, Inc., Fate Therapeutics Inc., Gilead Sciences, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Poseida Therapeutics Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., and Tessa Therapeutics Pte. Ltd..

Market Segmentation & Coverage

This research report categorizes the T-Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Modality
- Commercialized
- Research
Therapy Type
- CAR T-cell Therapy
- T Cell Receptor-Based
- Tumor Infiltrating Lymphocytes-Based
Indication
- Hematologic Malignancies
  - Leukemia
  - Lymphoma
  - Myeloma
- Solid Tumors
  - Brain & Central Nervous System
  - Liver Cancer
  - Melanoma

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing approvals along with expanding manufacturing capabilities
5.1.1.2. Alarming rate of increase in prevalence of cancers
5.1.1.3. Availability of adequate reimbursements with government awareness
5.1.2. Restraints
5.1.2.1. Limitations of efficacy of CAR T-cell immunotherapy and inadequate homing of CAR T-cells to tumor deposits
5.1.3. Opportunities
5.1.3.1. Exponential R&D funding for immuno-oncology sector
5.1.3.2. Expanding adoption of gene and cell therapy
5.1.4. Challenges
5.1.4.1. Safety issues and possible side-effects
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. T-Cell Therapy Market, by Modality

6.1. Introduction
6.2. Commercialized
6.3. Research

7. T-Cell Therapy Market, by Therapy Type

7.1. Introduction
7.2. CAR T-cell Therapy
7.3. T Cell Receptor-Based
7.4. Tumor Infiltrating Lymphocytes-Based

8. T-Cell Therapy Market, by Indication

8.1. Introduction
8.2. Hematologic Malignancies
8.2.1. Leukemia
8.2.2. Lymphoma
8.2.3. Myeloma
8.3. Solid Tumors
8.3.1. Brain & Central Nervous System
8.3.2. Liver Cancer
8.3.3. Melanoma

9. Americas T-Cell Therapy Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific T-Cell Therapy Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa T-Cell Therapy Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. T-CELL THERAPY MARKET RESEARCH PROCESS
FIGURE 2. T-CELL THERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL T-CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2023 VS 2030 (%)
FIGURE 7. GLOBAL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES T-CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES T-CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. T-CELL THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL T-CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. T-CELL THERAPY MARKET DYNAMICS
TABLE 7. GLOBAL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL T-CELL THERAPY MARKET SIZE, BY COMMERCIALIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL T-CELL THERAPY MARKET SIZE, BY T CELL RECEPTOR-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL T-CELL THERAPY MARKET SIZE, BY TUMOR INFILTRATING LYMPHOCYTES-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL T-CELL THERAPY MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL T-CELL THERAPY MARKET SIZE, BY BRAIN & CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL T-CELL THERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 41. CANADA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 42. CANADA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 43. CANADA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 44. CANADA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 45. CANADA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 46. MEXICO T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 47. MEXICO T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 48. MEXICO T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 49. MEXICO T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 50. MEXICO T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES T-CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 63. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 68. CHINA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 69. CHINA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 70. CHINA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. CHINA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 72. CHINA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 73. INDIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 74. INDIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 75. INDIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. INDIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 77. INDIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 78. INDONESIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 79. INDONESIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 83. JAPAN T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 84. JAPAN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 85. JAPAN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. JAPAN T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 87. JAPAN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 88. MALAYSIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 89. MALAYSIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 93. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 94. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 98. SINGAPORE T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 99. SINGAPORE T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 103. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 104. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 108. TAIWAN T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 109. TAIWAN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 113. THAILAND T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 114. THAILAND T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 115. THAILAND T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 116. THAILAND T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 117. THAILAND T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 118. VIETNAM T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 119. VIETNAM T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 129. DENMARK T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 130. DENMARK T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 131. DENMARK T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. DENMARK T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 133. DENMARK T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 134. EGYPT T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 135. EGYPT T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 136. EGYPT T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. EGYPT T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 138. EGYPT T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 139. FINLAND T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 140. FINLAND T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 141. FINLAND T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 142. FINLAND T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 143. FINLAND T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 144. FRANCE T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 145. FRANCE T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 146. FRANCE T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 147. FRANCE T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 148. FRANCE T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 149. GERMANY T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 150. GERMANY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 151. GERMANY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 152. GERMANY T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 153. GERMANY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 154. ISRAEL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 159. ITALY T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 160. ITALY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 161. ITALY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 162. ITALY T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 163. ITALY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 169. NIGERIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 170. NIGERIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 174. NORWAY T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 175. NORWAY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 176. NORWAY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 177. NORWAY T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 178. NORWAY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 179. POLAND T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 180. POLAND T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 181. POLAND T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 182. POLAND T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 183. POLAND T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 184. QATAR T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 185. QATAR T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 186. QATAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 187. QATAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 188. QATAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 204. SPAIN T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 205. SPAIN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 206. SPAIN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 207. SPAIN T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 208. SPAIN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 214. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 215. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 219. TURKEY T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 220. TURKEY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 221. TURKEY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 222. TURKEY T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 223. TURKEY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 234. T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
TABLE 235. T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the T-Cell Therapy Market, which are profiled in this report, include:

AbbVie Inc.
Adaptimmune Therapeutics PLC
Amgen Inc.
Bluebird Bio, Inc.
Bristol Myers Squibb
DiaCarta, Inc.
Fate Therapeutics Inc.
Gilead Sciences, Inc.
Merck KGaA
Novartis AG
Pfizer Inc.
Poseida Therapeutics Inc.
Sorrento Therapeutics, Inc.
Takara Bio Inc.
Tessa Therapeutics Pte. Ltd.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	182
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 9.85 Billion
Forecasted Market Value ( USD ) by 2030	$ 31.3 Billion
Compound Annual Growth Rate	21.2%
Regions Covered	Global
No. of Companies Mentioned	16

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3518EUR$3,545USD£2,920GBP €3909EUR$3,939USD£3,244GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6224EUR$6,272USD£5,166GBP €6915EUR$6,969USD£5,740GBP

Understanding Market Dynamics in the T-Cell Therapy Market

Exploring Porter’s Five Forces for the T-Cell Therapy Market

Applying PESTLE Analysis to the T-Cell Therapy Market

Analyzing Market Share in the T-Cell Therapy Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the T-Cell Therapy Market

Strategic Recommendations for Success in the T-Cell Therapy Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

CAR T-cell Therapy Market by Indication, Type, End-Use - Global Forecast 2025-2030

T-cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

CAR-T Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

T-Cell Immunotherapy Market by Mechanism Of Action, Product Class, Type of Therapy, Indication - Global Forecast 2025-2030

CAR T-cell Therapy - Global Strategic Business Report

About the T Cell Therapies Market